Amy Tenderich, founder of Diabetes Mine, on thinking like a patient

[Northerner]

A few months after Novo Nordisk gained FDA approval for its type-2 diabetes drug, Victoza, in January of 2010, Amy Tenderich sat down to write a review of the product on her blog, Diabetesmine.com. She quickly covered the drug?s vital stats?Victoza is an injectable glucagon-like peptide-1 designed to stimulate insulin secretion when high blood sugar is present?and then moved on to address the questions she knew would concern potential users: What type of patient would it benefit? How did it stack up against its competitor, Byetta? What were its side effects? What were its potential risks? What would happen when users combined Victoza with their usual oral anti-diabetes drugs?

http://medicinex.stanford.edu/2011/...-of-diabetes-mine-on-thinking-like-a-patient/